capecitabine has been researched along with Osteogenic Sarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B | 1 |
1 other study(ies) available for capecitabine and Osteogenic Sarcoma
| Article | Year |
|---|---|
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA; DNA-Binding Proteins; Drug Eruptions; Female; Fluorouracil; Gastrointestinal Neoplasms; Gene Frequency; Humans; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Minisatellite Repeats; Mucositis; Osteosarcoma; Polymorphism, Genetic; Thymidylate Synthase; Turkey; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein; Young Adult | 2012 |